QoL after multimodal treatment of rectal cancer with/without oxaliplatin (phase 3, CAO/ARO/AIO-04)

被引：0

作者：

Kosmala, R. ^{[1
]}

Fokas, E. ^{[2
,3
]}

Flentje, M. ^{[1
]}

Sauer, R. ^{[4
]}

Liersch, T. ^{[5
]}

Graeven, U. ^{[6
]}

Fietkau, R. ^{[4
]}

Hohenberger, W. ^{[7
]}

Arnold, D. ^{[8
]}

Hofheinz, R. ^{[9
]}

Ghadimi, M. ^{[5
]}

Raab, H. ^{[10
]}

Stroebel, P. ^{[11
]}

Staib, L. ^{[12
]}

Grabenbauer, G. G. ^{[13
]}

Folprecht, G. ^{[14
]}

Uter, W. ^{[15
]}

Gall, C. ^{[15
]}

Roedel, C. ^{[2
,3
]}

Polat, B. ^{[1
]}

机构：

[1] Univ Hosp Wurzburg, Dept Radiat Oncol, Wurzburg, Germany

[2] Goethe Univ Frankfurt, Frankfurt, Germany

[3] German Canc Consortium DKTK Partner Site, Dept Radiotherapy & Oncol, Frankfurt, Germany

[4] Univ Hosp Erlangen, Dept Radiat Oncol, Erlangen, Germany

[5] Univ Med Ctr Gottingen, Dept Gen Visceral & Paediat Surg, Gottingen, Germany

[6] Kliniken Maria Hilf GmbH Monchengladbach, Dept Haematol Oncol & Gastroenterol, Monchengladbach, Germany

[7] Univ Hosp Erlangen, Dept Surg, Erlangen, Germany

[8] Tumour Biol Ctr Freiburg, Freiburg, Germany

[9] Heidelberg Univ, Univ Hosp Mannheim, Interdisciplinary Tumour Ctr, Heidelberg, Germany

[10] Carl von Ossietzky Univ Oldenburg, Dept Gen & Visceral Surg, Oldenburg, Germany

[11] Univ Med Ctr Gottingen, Inst Pathol, Gottingen, Germany

[12] Klinikum Esslingen, Dept Surg, Esslingen, Germany

[13] DiaCura & Klinikum Coburg, Dept Radiat Oncol & Radiotherapy, Coburg, Germany

[14] Univ Hosp Carl Gustav Carus, Univ Canc Ctr, Med Dept 1, Dresden, Germany

[15] Univ Erlangen Nurnberg, Dept Med Informat Biometry & Epidemiol, Erlangen, Germany

来源：

RADIOTHERAPY AND ONCOLOGY | 2019年 / 133卷

关键词：

D O I：

10.1016/S0167-8140(19)30804-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OC-0384

引用

页码：S191 / S192

页数：2

共 50 条

[31] Neutrophilia as prognostic factor for outcome in the CAO/ARO/ALO-04 phase 3 rectal cancer trial
Diefenhardt, M.
Hofheinz, R.
Beissbarth, T.
Arnold, D.
von den Gruen, J. Mueller
Liersch, T.
Stroebel, P.
Grabenbauer, G.
Fietkau, R.
Weitz, J.
Ghadimi, M.
Roedel, C.
Fokas, E.
RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S256 - S257
[32] TNT in rectal cancer: Final results of the CAO/ARO/AIO-12 randomized phase 2 trial
Fokas, E.
Schlenska-Lange, A.
Polat, B.
Klautke, G.
Fietkau, R.
Kuhnt, T.
Brunner, T.
Grosu, A.
Kirste, S.
Flentje, M.
Germer, C.
Bechstein, W.
Friede, T.
Hofheinz, R.
Ghadimi, M.
Roedel, C.
RADIOTHERAPY AND ONCOLOGY, 2021, 161 : S199 - S200
[33] Quality of life following TNT of rectal cancer in the CAO/ARO/AIO-12 phase 2 trial
Kosmala, R.
Fokas, E.
Hammann, A. Salazar
Paulus, P.
Flentje, M.
Germer, C.
Ghadimi, M.
Hofheinz, R.
Diefenhardt, M.
Roedel, C.
Polat, B.
RADIOTHERAPY AND ONCOLOGY, 2023, 182 : S208 - S209
[34] Prognostic factors after neoadjuvant radiochemotherapy for rectal cancer: Update of the CAO/ARO/AIO-94 phase III study.
Sauer, R
Roedel, C
Martus, P
Fietkau, R
Wittekind, C
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 246S - 246S
[35] HER-2 as a potential target for rectal cancer treatment: Positivity rate in patients of the CAO/ARO/AIO-94 and-04 trial.
Conradi, Lena-Christin
Storch, Marcus
Nagelmeier, Iris
Styczen, Hanna
Wolff, Hendrik A.
Gaedcke, Jochen
Sprenger, Thilo
Homayounfar, Kia
Ghadimi, Michael
Rueschoff, Josef
Beissbarth, Tim
Roedel, Claus
Liersch, Torsten
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
[36] Pre-operative chemoradiotherapy and adjuvant chemotherapy with 5-FU in comparison with a pre-operative chemoradiotherapy and adjuvant chemotherapy with 5-Fu plus Oxaliplatin in localized advanced rectal cancer in UICC-stage 2 and 3 (CAO/ARO/AIO-04)
Sauer, R.
STRAHLENTHERAPIE UND ONKOLOGIE, 2010, 186 : 46 - 46
[37] Total neoadjuvant therapy for Organ Preservation in Rectal Cancer: The CAO/ARO/AIO-16 phase II trial
Gani, C.
Polat, B.
Ott, O.
Germer, E.
Koenigsrainer, A.
Kirschniak, A.
Clasen, S.
Grosse, U.
Diefenhardt, M.
Bitzer, M.
Reibetanz, J.
Martus, P.
Flentje, M.
Fietkau, R.
Fokas, E.
Zips, D.
Roedel, C. M.
RADIOTHERAPY AND ONCOLOGY, 2022, 170 : S751 - S751
[38] Prognosis factors after neoadjuvant radiochemotherapy of rectal cancer:: subgroup analysis of the CAO/ARO/AIO-94 study
Rödel, C
Fietkau, R
Martus, P
Wittekind, C
Hess, C
Sauer, R
STRAHLENTHERAPIE UND ONKOLOGIE, 2005, 181 : 57 - 57
[39] Total Neoadjuvant Therapy as Organ Preserving Therapy for Rectal Cancer: The CAO/ARO/AIO-16 Phase II Study
Gani, C.
Polat, B.
Ott, O.
Germer, E.
Koenigsrainer, A.
Kirschniak, A.
Clasen, S.
Grosse, U.
Diefenhardt, M.
Reibetanz, J.
Bitzer, M.
Martus, P.
Flentje, M.
Fietkau, R.
Fokas, E.
Zips, D.
Roedel, C.
STRAHLENTHERAPIE UND ONKOLOGIE, 2022, 198 (SUPPL 1) : S8 - S8
[40] The prognostic impact of surgical complications after combined modality treatment of rectal cancer: Long-term results of the CAO/ARO/AIO-94 trial
Sprenger, Thilo
Beissbarth, Tim
Fietkau, Rainer
Raab, Hans-Rudolf
Hohenberger, Werner
Liersch, Torsten
Roedel, Claus
Ghadimi, Michael
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)

← 1 2 3 4 5 →